We recently held a webinar on the topic of changes and updates to global API regulation in 2023. Teva api regulatory experts from across 5 different markets – US, EU, LATAM, Japan & China, came together to talk about what’s new in each market, and to share their insights about what to be looking out
We recently held a webinar on the topic of change management in Japan. Teva api regulatory and change management experts, Marianna Kishinevsky and Rinat Bordman, discussed the change management landscape in Japan and how we, at Teva api, utilize our local, dedicated team in Japan to navigate the complex and frequent changes that require control
We recently held a webinar on the topic of ‘Smart tracking of your APIs”. Teva api supply chain expert, Bertil Wagensveld, discussed the new GPS data logger that Teva api uses on cargo to give full transport visibility, all the way from when the shipment leaves our manufacturing site until it gets to your door!
Our recent webinar, Nitrosamines: A Moving Target was a deep-dive into the issue of Nitrosamines impurities and how you can stay on top of the various evaluation requirements to remain compliant. During the webinar, Diana Van Geenhoven, our head of global compliance, Lena Ben Moha-Lerman, Senior Director of Lifecycle Management within Teva api’s R&D team
At Teva api, we always remember how essential our work is to the wider community, and this was never more important than this past year, when the COVID-19 pandemic hit. As Teva’s Chairman, Dr Sol J Barer said, “At Teva, it reminded us of our responsibility to patients, our employees, communities and the planet. It
Completing a Good Manufacturing Practices (GMP) audit report prior to 2020 was simple. Companies had many ways to get theirs done, and a large percentage opted for performing their own onsite audits at their suppliers’ facilities, and then putting together the report themselves. This year however, with travel so limited, this option is difficult if
On April 1st, 2020, Brazil’s ANVISA published new landmark regulations referring to active pharmaceutical ingredients (APIs). This new set of rules consists of three separate guidelines for local pharmaceutical segment stakeholders, known as “RDCs”. These are RDC 359/2020, RDC 361/2020 and RDC 362/2020, and they represent a complete overhaul of the API regulatory landscape in